Litigation Details for Nalpropion Pharmaceuticals, Inc. v. Actavis Laboratories FL, Inc.. (D. Del. 2015)

Nalpropion Pharmaceuticals, Inc. v. Actavis Laboratories FL, Inc.. (D. Del. 2015)

Docket		Date Filed	2015-06-03
Court	District Court, D. Delaware	Date Terminated	2020-10-20
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Parties	TAKEDA PHARMACEUTICALS USA, INC.
Patents	7,375,111; 7,462,626; 8,088,786; 8,318,788; 8,722,085; 8,815,889; 8,916,195; 9,125,868
Attorneys	Monte Terrell Squire
Firms	Polsinelli PC
Link to Docket	External link to docket

Details for Nalpropion Pharmaceuticals, Inc. v. Actavis Laboratories FL, Inc.. (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-06-03				External link to document
2015-06-03	1		THE PATENTS-IN-SUIT 28. Orexigen owns United States Patent No. 7,375,111 (“the ’111…action for infringement of United States Patent Nos. 7,375,111; 7,462,626; 8,088,786; 8,318,788; 8,722,085… This is a civil action for patent infringement arising under the patent laws of the United States, …8,916,195 (collectively, “the patents- in-suit”). This action arises under the Patent Laws of the United States…111 patent”) titled “Compositions for Affecting Weight Loss.” The ’111 patent was duly and legally issued	External link to document
2015-06-03	181		and Proposed Order of Dismissal of U.S. Patent No. 9,125,868 and Certain Other Claims, by Actavis Laboratories…2015 20 October 2020 1:15-cv-00451 830 Patent None District Court, D. Delaware	External link to document

Nalpropion Pharmaceuticals v. Actavis Laboratories Florida: Litigation Summary and Patent Analysis

Last updated: August 2, 2026

Nalpropion Pharmaceuticals sued Actavis Laboratories FL in the U.S. District Court for the District of Delaware after Actavis filed an abbreviated new drug application seeking approval for a generic version of Contrave, Nalpropion’s extended-release naltrexone and bupropion product. The case, No. 1:15-cv-00451, was an ANDA patent action under 21 U.S.C. § 355(j) and 35 U.S.C. § 271(e)(2).

The dispute focused on patents covering the composition and use of the naltrexone-bupropion combination for weight management. The Federal Circuit ultimately affirmed the invalidity ruling against the asserted patent claims, removing those claims as a barrier to Actavis’s ANDA approval and generic entry strategy. The decision is reported at 934 F.3d 1344 (Fed. Cir. 2019). [1]

What was Nalpropion Pharmaceuticals v. Actavis Laboratories about?

Nalpropion alleged that Actavis’s ANDA product would infringe patents listed for Contrave. Actavis responded with Paragraph IV certifications asserting that the relevant patent claims were invalid, unenforceable, or would not be infringed.

The case involved two principal Contrave patents:

Patent	General subject matter	Litigation relevance
U.S. Patent No. 8,273,735	Extended-release naltrexone and bupropion compositions	Core composition patent asserted against Actavis
U.S. Patent No. 8,778,389	Naltrexone-bupropion treatment methods and related pharmaceutical formulations	Asserted patent covering use of the combination for weight management

The patents were associated with Nalpropion and its predecessor or affiliated entities in the Contrave development program. Contrave was developed by Orexigen Therapeutics and later commercialized by Nalpropion.

The technical dispute concerned whether combining known pharmacologic agents, naltrexone and bupropion, in a sustained-release formulation for weight loss involved an inventive step. The Federal Circuit considered prior-art disclosures, motivation to combine, expectation of success, and objective evidence of nonobviousness. [1]

When was the case filed and what court handled it?

Nalpropion filed the action in the District of Delaware in 2015 under case number 1:15-cv-00451.

Event	Date or period
Complaint filed	2015
District court proceedings	2015-2018
Federal Circuit appeal	2018-2019
Federal Circuit decision	August 2019
Federal Circuit citation	934 F.3d 1344

The case was assigned to the District of Delaware, a major forum for pharmaceutical ANDA litigation. The action was part of the statutory Hatch-Waxman process triggered by Actavis’s Paragraph IV certifications.

What was Actavis’s Paragraph IV challenge?

Actavis’s Paragraph IV position challenged the enforceability of Nalpropion’s patent rights before patent expiration. A Paragraph IV certification states that a listed patent is invalid, unenforceable, or not infringed. Filing a Paragraph IV certification can expose the ANDA applicant to an infringement action under 35 U.S.C. § 271(e)(2).

The litigation therefore addressed more than an ordinary commercial dispute. A final judgment of patent validity could delay approval or launch of Actavis’s generic product. A judgment of invalidity could remove the principal patent-based obstacle to FDA approval and commercialization.

The asserted claims were challenged primarily on obviousness grounds. Actavis argued that the claimed combination and treatment approach would have been obvious in light of prior-art references describing:

• Bupropion as an active pharmaceutical ingredient with effects relevant to weight management.
• Naltrexone as an opioid antagonist with potential effects on appetite or reward pathways.
• Use of combination therapies in obesity treatment.
• Sustained-release dosage forms for the individual agents.
• Pharmacologic rationale for combining the two agents.

What did the district court decide?

The district court held that the asserted claims were invalid for obviousness. The analysis considered whether a person of ordinary skill in the art would have been motivated to combine naltrexone and bupropion and whether the claimed formulation and therapeutic use would have been reasonably expected to succeed.

The court also evaluated Nalpropion’s evidence of secondary considerations, including commercial success and alleged unexpected results. The court concluded that the evidence did not overcome the showing of obviousness.

The central issue was not whether Contrave was commercially successful. It was whether the asserted patent claims claimed a technically nonobvious advance over the prior art. Commercial success can support patent validity only when the success is sufficiently linked to the claimed features and is not primarily attributable to unclaimed factors such as marketing, regulatory approval, or market demand.

How did the Federal Circuit rule?

The Federal Circuit affirmed the district court’s obviousness determination. The appellate court treated the case as a fact-intensive obviousness dispute and upheld the district court’s findings regarding the prior art, motivation to combine, and expectation of success. [1]

The decision reinforced several principles relevant to pharmaceutical patent litigation:

1. A combination of known drugs can be obvious even when the combination later produces a commercially successful product.
2. A pharmacologic rationale can support a motivation to combine where the prior art provides a reason to investigate the claimed combination.
3. Unexpected results must be commensurate with the scope of the claims.
4. Commercial success has limited force when the evidence does not establish a strong nexus to the patented technical features.
5. A formulation patent cannot rely solely on the commercial value of the active ingredients if the formulation limitations were predictable from the prior art.

The Federal Circuit’s ruling left the asserted claims unavailable as a basis for blocking Actavis’s ANDA product.

Which patents protected Contrave in the Actavis litigation?

Contrave’s patent estate included composition, formulation, and method-of-use rights. The two patents most closely associated with the Nalpropion v. Actavis litigation were the ’735 and ’389 patents.

U.S. Patent No. 8,273,735

The ’735 patent covered pharmaceutical compositions containing naltrexone and bupropion in an extended-release dosage form. Its value rested on the combination of:

• The active ingredients.
• Relative amounts or ratios of the ingredients.
• Extended-release delivery.
• Dosage-form limitations.
• Weight-management utility.

The Federal Circuit litigation treated the patent as vulnerable to an obviousness challenge based on prior-art teachings concerning the individual drugs, weight-loss treatment, and sustained-release formulations.

U.S. Patent No. 8,778,389

The ’389 patent covered aspects of using naltrexone and bupropion for treating obesity or overweight conditions. Method-of-use claims can provide meaningful protection after a composition patent becomes vulnerable, but their strength depends on whether the claimed patient population, dose, treatment regimen, or therapeutic result adds a nonobvious limitation.

The Actavis case demonstrated the risk that method claims directed to a known pharmacologic combination may be invalidated when the prior art supplies a reason to use the combination for the claimed indication.

What was the FDA and Orange Book status?

Contrave was approved by the FDA in 2014 as an extended-release tablet containing naltrexone hydrochloride and bupropion hydrochloride. The product is approved for chronic weight management in adults with obesity or overweight status accompanied by weight-related conditions, together with a reduced-calorie diet and increased physical activity. [2]

The FDA Orange Book listed patents associated with Contrave. Orange Book listing does not establish patent validity. It identifies patents that the reference product sponsor submitted for listing and that may trigger certification obligations for ANDA applicants.

The relevant FDA pathway was an ANDA, not a biologics license application. Contrave is a small-molecule drug, so biosimilar provisions under the Public Health Service Act do not apply. Generic applicants use the ANDA pathway and must demonstrate pharmaceutical equivalence, bioequivalence, and compliance with applicable labeling and manufacturing requirements.

When do Contrave patents lose exclusivity?

Patent expiration must be assessed patent by patent. The relevant date can be affected by patent-term adjustment, patent-term extension, terminal disclaimers, pediatric exclusivity, and later-issued continuation patents.

The ’735 and ’389 patents were not equivalent to a single, unified Contrave exclusivity date. The composition patent and method patents had different filing histories and potentially different expiration dates. The Federal Circuit’s 2019 invalidity ruling was commercially more important than the nominal expiration dates because it eliminated the asserted claims as a litigation barrier before their ordinary patent terms ended.

FDA regulatory exclusivity was separate from patent protection. Contrave’s approval in 2014 created a period of regulatory exclusivity, but FDA exclusivity did not independently prevent all future ANDA filings after the applicable statutory period. Patent rights and FDA exclusivity therefore had to be analyzed separately.

What was the commercial effect of the ruling?

The decision weakened the principal patent-based defense for Contrave against Actavis’s generic product. Its effect included:

• Reduced ability to delay ANDA approval through the asserted patents.
• Increased risk of generic competition after FDA approval.
• Lower value for the invalidated claims in licensing or settlement negotiations.
• Greater importance for any unasserted patents, later-issued continuation patents, regulatory exclusivity, and manufacturing controls.
• Greater exposure for Contrave revenue once a generic applicant could satisfy FDA requirements.

The ruling did not automatically guarantee immediate commercial launch. FDA approval, manufacturing readiness, supply arrangements, labeling, court orders, and any separate patents or settlement obligations could still affect launch timing. The decision did, however, remove the asserted patents as a basis for maintaining an injunction against the Actavis ANDA product.

Which companies challenged Contrave patents?

Actavis Laboratories FL, Inc., part of the Actavis and Allergan generic-drug organizations, was the defendant in the reported action. The company challenged Nalpropion’s patent rights through the ANDA Paragraph IV process.

The case should be distinguished from later or parallel challenges involving other ANDA applicants. Different generic applicants may have filed separate ANDAs, certifications, or litigation involving different Orange Book-listed patents. A judgment in one ANDA case does not automatically determine the rights of every other applicant, although a Federal Circuit holding on claim validity can materially affect later cases involving the same claims.

Was there a settlement agreement?

The reported Federal Circuit decision establishes the adjudicated appellate outcome. The public litigation record most relevant to the case is the district court judgment and Federal Circuit decision.

A settlement, license, or authorized-generic arrangement would have to be evaluated separately from the merits judgment. The Federal Circuit opinion did not convert the case into a settlement-based entry date. The operative legal result was the affirmance of invalidity for the asserted claims.

How strong was Nalpropion’s patent estate?

The estate had commercial relevance but limited litigation strength for the claims adjudicated in this case.

Patent estate element	Assessment
Active-ingredient combination	Vulnerable where prior art disclosed both agents and a rationale for combination
Extended-release formulation	Vulnerable where sustained-release techniques were known or predictable
Weight-management method claims	Vulnerable when prior art suggested the indication and combination
Commercial success evidence	Insufficient to overcome the obviousness record in the appellate decision
Regulatory approval	Supported market value but did not establish patent validity
Biosimilar protection	Not applicable because Contrave is a small molecule
Manufacturing barriers	Potentially relevant commercially, but not a substitute for valid patent claims
Later continuation patents	Required separate claim-by-claim review

The case illustrates the difference between product value and patent strength. Contrave had an approved product, an established indication, and commercial market value. Those factors did not preserve patent claims that the courts found obvious.

What generic launch risks remained after the decision?

After the Federal Circuit ruling, the remaining barriers to generic entry were primarily regulatory and operational rather than the invalidated claims.

Potential launch constraints included:

• FDA review and approval of Actavis’s ANDA.
• Demonstration of bioequivalence for the extended-release product.
• Compliance with controlled manufacturing and quality requirements.
• Availability of commercial-scale product.
• Any unasserted or later-issued patents.
• Possible pediatric or regulatory exclusivity.
• Labeling disputes involving patented methods of use.
• Commercial risk from price erosion and market-share competition.

A generic launch could reduce Contrave net sales through price competition, formulary substitution, and pharmacy-level substitution. The magnitude would depend on the number of approved competitors, contracting arrangements, payer coverage, and whether Nalpropion maintained an authorized-generic or other defensive strategy.

Key Takeaways

• Nalpropion sued Actavis in the District of Delaware in 2015 over a generic Contrave ANDA.
• The dispute centered on U.S. Patent Nos. 8,273,735 and 8,778,389.
• Actavis used Paragraph IV certifications to challenge the asserted patents.
• The district court found the asserted claims obvious.
• The Federal Circuit affirmed the invalidity ruling in 2019. [1]
• The decision removed the asserted claims as a patent barrier to Actavis’s generic strategy.
• Contrave is a small-molecule drug, so biosimilar rules do not apply.
• FDA Orange Book listing did not establish validity and did not override the court’s judgment.
• Later patents, regulatory exclusivity, manufacturing capability, and FDA approval remained separate issues.
• The case reduced the litigation strength and commercial leverage of the asserted Contrave patents.

FAQs About Nalpropion Pharmaceuticals v. Actavis

What drug was at issue in the Nalpropion Actavis case?

The case involved Contrave, an extended-release combination of naltrexone hydrochloride and bupropion hydrochloride approved for chronic weight management.

Did Actavis win the Contrave patent case?

Actavis prevailed on the core patent-validity issue. The Federal Circuit affirmed the ruling that the asserted claims were invalid for obviousness.

Did the case involve a biosimilar?

No. Contrave is a small-molecule drug. The challenge proceeded through the ANDA and Hatch-Waxman framework, not the biosimilar pathway.

Does invalidation of the ’735 patent invalidate every Contrave patent?

No. The judgment applies to the claims and patents adjudicated in the case. Other patents, continuation applications, and later-issued claims require separate analysis.

Did the Federal Circuit authorize an immediate generic launch?

No. The ruling removed the asserted patent claims as a litigation barrier. FDA approval, regulatory exclusivity, manufacturing readiness, and other patent or settlement issues could still affect launch timing.

References

1. Nalpropion Pharmaceuticals, Inc. v. Actavis Laboratories FL, Inc., 934 F.3d 1344 (Fed. Cir. 2019).

2. U.S. Food and Drug Administration. (2024). Drugs@FDA: Contrave (naltrexone hydrochloride and bupropion hydrochloride) extended-release tablets, NDA 200063. FDA.

3. U.S. Patent and Trademark Office. (2012). U.S. Patent No. 8,273,735: Sustained release bupropion and naltrexone compositions. U.S. Department of Commerce.

4. U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,778,389: Methods of treating overweight and obesity. U.S. Department of Commerce.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.